FDA Approves TOFACITINIB — Orient Pharma Co., Ltd. Yunlin Plant

Orient Pharma Co., Ltd. has received FDA approval for its ANDA to manufacture tofacitinib citrate oral tablets, a move that signals the company’s entry into the lucrative rheumatology market. This approval provides the full-spectrum manufacturer with a significant expansion of its generic portfolio, positioning it to capitalize on the high-volume demand for a widely used immune disorder treatment.